Pegsunercept
From Self-sufficiency
Revision as of 17:27, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))
| Clinical data | |
|---|---|
| Routes of administration | subcutaneous injection |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| CAS Number | 330988-75-5 |
| ATC code | none |
| Chemical data | |
| Formula | C502H758N154O165S16 |
| Molar mass | 12,103 g/mol (protein part)[[Script error: No such module "String".]] |
Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010[update], Phase II clinical trials have been completed.[1][2][3] It is being developed by Amgen.
Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.[3]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ ClinicalTrials.gov NCT00037700 Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
- ↑ ClinicalTrials.gov NCT00111423 Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)
- ↑ 3.0 3.1 Furst, DE; Fleischmann, R; Kopp, E; Schiff, M; Edwards C, 3rd; Solinger, A; Macri, M; 990136 Study, Group (2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of rheumatology. 32 (12): 2303–10. PMID 16331754.
Categories:
- Pages with script errors
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from January 2010
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- TNF-alpha inhibitors
- Immunosuppressants
- Pages with broken file links
- Antineoplastic and immunomodulating drug stubs
